XIE, SINING
XIE, SINING
Predictors and benefits of lipid-lowering therapy initiation after an atherosclerotic cardiovascular event: a retrospective cohort study
2025 M. Casula, S. Scotti, F. Galimberti, G. Matteo Bruno, G. Lorenzo Colombo, A. Alieva, S. Xie, A.L. Catapano, E. Olmastroni
Colchicine and cardiovascular events: An updated meta-analysis of published randomized controlled trials
2025 S. Xie, F. Galimberti, E. Olmastroni, A.L. Catapano, M. Casula
Contribution and interaction of polygenic predisposition and family history of coronary heart disease in predicting cardiovascular risk
2025 F. Galimberti, E. Olmastroni, M. Casula, S. Xie, A.L. Catapano
Operational Definitions of Polypharmacy and Their Association with All-Cause Hospitalization Risk: A Conceptual Framework Using Administrative Databases
2025 S. Scotti, L. Scotti, F. Galimberti, S. Xie, M. Casula, E. Olmastroni
Effect on C‐reactive protein levels of the addition of ezetimibe, bempedoic acid, or colchicine to statin treatment: A network meta‐analysis
2024 S. Xie, F. Galimberti, E. Olmastroni, A.L. Catapano, M. Casula
USE OF MULTIPLE ANALYTIC APPROACHES TO IDENTIFY NEW MARKERS/RISK FACTORS FOR CARDIOVASCULAR DISEASES AND EVALUATE THEIR ROLE AS POSSIBLE PHARMACOLOGICAL TARGETS
2024 S. Xie
Ezetimibe: Integrating Established Use with New Evidence - A Comprehensive Review
2024 E. Olmastroni, S. Scotti, F. Galimberti, S. Xie, M. Casula
Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials
2024 S. Xie, F. Galimberti, E. Olmastroni, T.F. Luscher, S. Carugo, A.L. Catapano, M. Casula, C. Wanner, S. Yusuf, A. Maggioni, A. Kirby, H. Ogawa, E.K. Hoogeveen, I. Seljeflot, K. Welty, M. Benderly, J.E. Manson, K. Wolski, C.P. Cannon, F.J. Raal, D. Kallend, J. Foody, M. Louie
HDL in atherosclerotic cardiovascular disease : In search of a role
2021 M. Casula, O. Colpani, S. Xie, A.L. Catapano, A. Baragetti